Matthew A Sexton
Overview
Explore the profile of Matthew A Sexton including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
13
Citations
668
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Senefeld J, Gorman E, Johnson P, Moir M, Klassen S, Carter R, et al.
Mayo Clin Proc Innov Qual Outcomes
. 2023 Oct;
7(5):499-513.
PMID: 37859995
Objective: To examine the association of COVID-19 convalescent plasma transfusion with mortality and the differences between subgroups in hospitalized patients with COVID-19. Patients And Methods: On October 26, 2022, a...
2.
Klompas A, van Helmond N, Juskewitch J, Pruthi R, Sexton M, Diaz Soto J, et al.
Sci Rep
. 2022 Jan;
12(1):637.
PMID: 35022488
Convalescent plasma is used to treat COVID-19. There are theoretical concerns about the impact of pro-coagulant factors in convalescent plasma on the coagulation cascade particularly among patients with severe COVID-19....
3.
Senefeld J, Johnson P, Kunze K, Bloch E, van Helmond N, Golafshar M, et al.
PLoS Med
. 2021 Dec;
18(12):e1003872.
PMID: 34928960
Background: The United States (US) Expanded Access Program (EAP) to coronavirus disease 2019 (COVID-19) convalescent plasma was initiated in response to the rapid spread of severe acute respiratory syndrome coronavirus...
4.
Kunze K, Johnson P, van Helmond N, Senefeld J, Petersen M, Klassen S, et al.
Nat Commun
. 2021 Aug;
12(1):4864.
PMID: 34381030
Successful therapeutics and vaccines for coronavirus disease 2019 (COVID-19) have harnessed the immune response to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Evidence that SARS-CoV-2 exists as locally evolving variants...
5.
Senefeld J, Johnson P, Kunze K, van Helmond N, Klassen S, Wiggins C, et al.
medRxiv
. 2021 Apr;
PMID: 33851175
Background: The United States (US) Expanded Access Program (EAP) to COVID-19 convalescent plasma was initiated in response to the rapid spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the...
6.
Joyner M, Carter R, Senefeld J, Klassen S, Mills J, Johnson P, et al.
N Engl J Med
. 2021 Feb;
384(11):1015-1027.
PMID: 33523609
Background: Convalescent plasma has been widely used to treat coronavirus disease 2019 (Covid-19) under the presumption that such plasma contains potentially therapeutic antibodies to severe acute respiratory syndrome coronavirus 2...
7.
Esmaeilzadeh S, DSouza R, Stewart T, Sexton M
Case Rep Anesthesiol
. 2020 Oct;
2020:8835533.
PMID: 33005456
Trichorhinophalangeal syndrome (TRPS) is a genetic disorder that may pose anesthetic challenges. We present a case of airway management for urgent surgery in a 56-year-old female with TRPS and difficult...
8.
Joyner M, Bruno K, Klassen S, Kunze K, Johnson P, Lesser E, et al.
Mayo Clin Proc
. 2020 Aug;
95(9):1888-1897.
PMID: 32861333
Objective: To provide an update on key safety metrics after transfusion of convalescent plasma in hospitalized coronavirus 2019 (COVID-19) patients, having previously demonstrated safety in 5000 hospitalized patients. Patients And...
9.
Joyner M, Senefeld J, Klassen S, Mills J, Johnson P, Theel E, et al.
medRxiv
. 2020 Aug;
PMID: 32817978
Importance: Passive antibody transfer is a longstanding treatment strategy for infectious diseases that involve the respiratory system. In this context, human convalescent plasma has been used to treat coronavirus disease...
10.
Awari D, Shah A, Sexton A, Sexton M
Case Rep Infect Dis
. 2020 Aug;
2020:8888270.
PMID: 32774953
Management of infections in the immunocompromised patient requires unique considerations that are not typically seen in the immunocompetent. Immunocompromised hosts require a broad set of differential diagnoses when presenting with...